Regeneron Pharmaceuticals, Inc. Declares Quarterly Dividend of $0.94 (NASDAQ:REGN)

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) declared a quarterly dividend on Thursday, July 30th. Stockholders of record on Tuesday, August 18th will be paid a dividend of 0.94 per share by the biopharmaceutical company on Monday, August 31st. This represents a c) annualized dividend and a dividend yield of 0.5%. The ex-dividend date of this dividend is Tuesday, August 18th.

Regeneron Pharmaceuticals has a payout ratio of 9.6% indicating that its dividend is sufficiently covered by earnings. Analysts expect Regeneron Pharmaceuticals to earn $42.26 per share next year, which means the company should continue to be able to cover its $3.76 annual dividend with an expected future payout ratio of 8.9%.

Regeneron Pharmaceuticals Price Performance

Shares of NASDAQ REGN traded up $42.92 during mid-day trading on Thursday, reaching $738.34. The company’s stock had a trading volume of 1,460,610 shares, compared to its average volume of 859,543. The firm has a market capitalization of $78.06 billion, a PE ratio of 17.99, a P/E/G ratio of 27.77 and a beta of 0.24. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.57 and a quick ratio of 2.96. The stock has a fifty day moving average of $638.74 and a two-hundred day moving average of $711.76. Regeneron Pharmaceuticals has a 52 week low of $541.00 and a 52 week high of $821.11.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its earnings results on Thursday, July 30th. The biopharmaceutical company reported $14.29 earnings per share (EPS) for the quarter, topping the consensus estimate of $10.16 by $4.13. The firm had revenue of $4.29 billion during the quarter, compared to analysts’ expectations of $3.82 billion. Regeneron Pharmaceuticals had a return on equity of 13.16% and a net margin of 29.65%.The firm’s revenue was up 16.7% on a year-over-year basis. During the same quarter last year, the business posted $12.81 earnings per share. As a group, sell-side analysts anticipate that Regeneron Pharmaceuticals will post 2.06 EPS for the current fiscal year.

Insider Transactions at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, Director Arthur F. Ryan sold 200 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Thursday, July 2nd. The stock was sold at an average price of $650.15, for a total value of $130,030.00. Following the sale, the director owned 17,303 shares of the company’s stock, valued at $11,249,545.45. The trade was a 1.14% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 6.97% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the business. Wedge Capital Management L L P NC grew its stake in shares of Regeneron Pharmaceuticals by 20.3% in the 2nd quarter. Wedge Capital Management L L P NC now owns 47,775 shares of the biopharmaceutical company’s stock worth $29,790,000 after buying an additional 8,063 shares in the last quarter. Insight Wealth Strategies LLC raised its position in shares of Regeneron Pharmaceuticals by 26.9% during the 2nd quarter. Insight Wealth Strategies LLC now owns 8,734 shares of the biopharmaceutical company’s stock valued at $5,456,000 after buying an additional 1,850 shares in the last quarter. Tema ETFs LLC lifted its holdings in shares of Regeneron Pharmaceuticals by 2.3% in the 2nd quarter. Tema ETFs LLC now owns 5,481 shares of the biopharmaceutical company’s stock valued at $3,418,000 after acquiring an additional 121 shares during the last quarter. E. Ohman J or Asset Management AB lifted its holdings in shares of Regeneron Pharmaceuticals by 35.2% in the 2nd quarter. E. Ohman J or Asset Management AB now owns 3,840 shares of the biopharmaceutical company’s stock valued at $2,394,000 after acquiring an additional 1,000 shares during the last quarter. Finally, Harrell Investment Partners LLC grew its position in Regeneron Pharmaceuticals by 1.3% in the second quarter. Harrell Investment Partners LLC now owns 2,089 shares of the biopharmaceutical company’s stock worth $1,303,000 after acquiring an additional 27 shares in the last quarter. 83.31% of the stock is owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.